Multiple lines of evidence demonstrated that GALNT2 was dysregulated in several solid tumors, such as glioma [17], neuroblastoma [18], gastric adenocarcinoma [19], oral squamous cell carcinoma [20], and hepatocellular carcinoma [21]. Here, GALNT2 is linked to hepatocellular carcinoma.